A3P Biomedical appoints Anders Martin-Löf as new CFO

May 18, 2022

A3P Biomedical has appointed Anders Martin-Löf as Chief Financial Officer (CFO). Anders Martin-Löf brings more than 20 years’ experience from the life science industry, including CFO positions at Oncopeptides, Wilson Therapeutics and RaySearch Laboratories. He will take up his new position at A3P Biomedical in August and report to CEO David Rosén.

“I am very pleased that we have been able to recruit Anders Martin-Löf as our new CFO. With broad experience from the industry and several challenging CFO positions, Anders will be a great addition to the management team. Following our recent successfully completed private placement, we are now able to accelerate the commercial expansion of Stockholm3 and offer significantly improved prostate cancer diagnostics to more healthcare providers and men. I look forward to working closely with Anders and would also like to thank our board member Cecilia Edström for stepping in as acting CFO during the recruitment process,” says David Rosén CEO of A3P Biomedical.

“Stockholm3 can make a big difference in the fight against cancer and I believe that there is great potential both for patients and health-care providers in using it as standard of care for early detection of prostate cancer, the second most common cancer in men worldwide. I am really excited about joining A3P Biomedical and look forward to contributing to the global clinical roll-out, and increased patient and shareholder value,” says Anders Martin-Löf.

Anders Martin-Löf is 50 years old and holds an MSc in Engineering Physics, from the Royal Institute of Technology (KTH), and BA major in business administration, from the Stockholm and Uppsala Universities. Most recently, he has been CFO of Oncopeptides AB and prior to that, he served as CFO of Wilson Therapeutics AB and RaySearch Laboratories AB. Anders Martin-Löf also has experience from various commercial positions in the life science industry and as a management consultant at the Boston Consulting Group.

Anders Martin-Löf will take up his new position in mid-August and succeeds Cecilia Edström who has been acting CFO since February 2022.

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company’s lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

(1) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

A3P Biomedical appoints Anders Martin-Löf as new CFO

Documents